October 10th 2024
Medical experts discuss multidisciplinary approaches to GVHD.
October 3rd 2024
Medical experts discuss the role of patient-reported outcomes in cGVHD.
Medical experts discuss emerging trends in chronic GVHD treatment.
September 26th 2024
Medical experts discuss the mechanism of action within axatilimab.
Medical experts discuss the recent updates presented at ASH 2023 and TANDEM 2024.
September 19th 2024
Medical experts discuss treatment selection for a specific clinical scenario.
Medical experts discuss considerations for third-line treatment in chronic GVHD.
September 12th 2024
Medical experts discuss the data that led to belumosudil’s FDA approval.
Medical experts discuss advanced therapies in cGVHD.
September 5th 2024
Medical experts discuss criteria for switching GVHD treatments and how to choose between available treatment options.
Medical experts discuss overall goals for cGVHD treatment as well as concerns with long-term corticosteroid use in treatment.
August 29th 2024
Medical experts discuss navigating chronic GVHD.
After a brief introduction, Shernan Holtan, MD, and Haris Ali, MD, discuss the distinction between acute and chronic graft-vs-host disease.
October 11th 2022
Haris Ali, MD, discusses a phase 1 dose-escalation trial investigating the administration of selinexor in combination with ruxolitinib for patients with treatment-naïve myelofibrosis.
September 30th 2022
Haris Ali, MD, discusses the investigation of ruxolitinib and navitoclax combination therapy in myelofibrosis.
May 6th 2022
Expert perspectives on novel transplantation strategies to prevent or improve outcomes in graft-versus-host disease.
Brief insight on the FLIGHT and AGAVE-201 trials in chronic GVHD, which analyzed itacitinib, a JAK inhibitor, and axatilimab, a CSF1R inhibitor, respectively.
April 29th 2022
Considerations for novel treatment approaches with approved agents in combination or the frontline setting of chronic graft-vs-host disease.
Shared insight on how best to select ibrutinib, belumosudil, or ruxolitinib for patients with steroid-refractory chronic graft-vs-host disease.
April 22nd 2022
Closing out his summation of ruxolitinib in chronic GVHD, Yi-Bin Chen, MD, considers how real-world use compares with the REACH3 trial results.